enGene Therapeutics (ENGN) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed enGene Therapeutics (ENGN) over the past year, losing 57.4% versus a loss of 76.0%. enGene Therapeutics is the larger company by market cap ($119.3 million vs $112.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | INO |
|---|---|---|
| Share price | $1.78 | $1.09 |
| Market cap | $119.29M | $112.70M |
| 1-day change | +2.01% | -5.63% |
| YTD return | -80.29% | -37.36% |
| 1-year return | -75.98% | -57.42% |
| 5-year return | — | -98.71% |
| EPS (TTM) | $-2.07 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.25 | $2.72 |
| 52-week low | $1.40 | $0.56 |
| Distance from 52-week high | -85.47% | -59.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +84.83% | +190.83% |
| Average volume | 746.58K | 3.86M |
| Shares outstanding | 67.02M | 103.40M |
| Employees | 81 | 112 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed ENGN by 18.6 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Healthcare · Biotechnology · 81 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Healthcare · Biotechnology · 112 employees
ENGN vs INO FAQ
Which is bigger, enGene Therapeutics or Inovio Pharmaceuticals?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $119.29M compared with $112.70M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, ENGN or INO?
INO returned -57.42% over the past 12 months, compared with -75.98% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.